Cargando…

Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice

Objective: Obeticholic acid (OCA), a potent farnesoid X receptor (FXR) agonist, is a promising drug for nonalcoholic fatty liver disease (NAFLD); however, it can cause liver injury, especially at high doses. Here, we investigated the role of FXR in the high-dose OCA-induced hepatoxicity in the condi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Chuangzhen, Yu, Bingqing, Chen, Lixin, Zhang, Zhaohui, Ye, Weixiang, Zhong, Hui, Bai, Wenke, Yang, Yuping, Nie, Biao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124937/ https://www.ncbi.nlm.nih.gov/pubmed/35614939 http://dx.doi.org/10.3389/fphar.2022.880508

Ejemplares similares

The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma
por: Di Matteo, S., et al.
Publicado: (2019)

CHOP Regulates Endoplasmic Reticulum Stress-Mediated Hepatoxicity Induced by Monocrotaline
por: Guo, Yazhou, et al.
Publicado: (2021)

Unaltered Liver Regeneration in Post-Cholestatic Rats Treated with the FXR Agonist Obeticholic Acid
por: de Haan, Lianne R., et al.
Publicado: (2021)

Urine Metabolomics Study on Potential Hepatoxic Biomarkers Identification in Rats Induced by Aurantio-Obtusin
por: Xu, Longlong, et al.
Publicado: (2020)

The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease
por: Zhang, Dan-Ying, et al.
Publicado: (2019)

FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis
por: Verbeke, Len, et al.
Publicado: (2016)

Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models
por: Zhang, Yuanyuan, et al.
Publicado: (2017)

FXR agonist obeticholic acid induces liver growth but exacerbates biliary injury in rats with obstructive cholestasis
por: van Golen, Rowan F., et al.
Publicado: (2018)

Obeticholic acid and ferrostatin-1 differentially ameliorate non-alcoholic steatohepatitis in AMLN diet-fed ob/ob mice
por: Li, Shengjie, et al.
Publicado: (2022)

Vedolizumab-Associated Hypereosinophilia and Hepatoxicity
por: De Marco, Davide, et al.
Publicado: (2022)

Ginsenoside Rc, as an FXR activator, alleviates acetaminophen-induced hepatotoxicity via relieving inflammation and oxidative stress
por: Zhong, Yadi, et al.
Publicado: (2022)

The FXR Agonist, Obeticholic Acid, Suppresses HCC Proliferation & Metastasis: Role of IL-6/STAT3 Signalling Pathway
por: Attia, Yasmeen M., et al.
Publicado: (2017)

Activation of Sirt1/FXR Signaling Pathway Attenuates Triptolide-Induced Hepatotoxicity in Rats
por: Yang, Jing, et al.
Publicado: (2017)

Alterations in the gut microbiota and serum metabolomics of spontaneous cholestasis caused by loss of FXR signal in mice
por: Wei, Shizhang, et al.
Publicado: (2023)

DDAH1 Protects against Acetaminophen-Induced Liver Hepatoxicity in Mice
por: Shen, Xiyue, et al.
Publicado: (2022)

Emodin Rescues Intrahepatic Cholestasis via Stimulating FXR/BSEP Pathway in Promoting the Canalicular Export of Accumulated Bile
por: Xiong, Xiao-Li, et al.
Publicado: (2019)

Propylthiouracil (PTU) Hepatoxicity in Children and Recommendations for Discontinuation of Use
por: Rivkees, Scott A., et al.
Publicado: (2009)

Drug-induced diabetes and hepatoxicity in COVID-19 patients
por: Ghosh, Rajdeep, et al.
Publicado: (2022)

Exposure to Bisphenol A Caused Hepatoxicity and Intestinal Flora Disorder in Rats
por: Liu, Ruijing, et al.
Publicado: (2022)

Bacteroides dorei BDX-01 alleviates DSS-induced experimental colitis in mice by regulating intestinal bile salt hydrolase activity and the FXR-NLRP3 signaling pathway
por: Sun, Xiaowei, et al.
Publicado: (2023)

Activation of FXR by obeticholic acid induces hepatic gene expression of SR-BI through a novel mechanism of transcriptional synergy with the nuclear receptor LXR
por: Dong, Bin, et al.
Publicado: (2019)

Untargeted and Targeted Metabolomics Reveal the Underlying Mechanism of Aspirin Eugenol Ester Ameliorating Rat Hyperlipidemia via Inhibiting FXR to Induce CYP7A1
por: Xiao-Rong, Lu, et al.
Publicado: (2021)

Effects of Poria cocos extract on metabolic dysfunction-associated fatty liver disease via the FXR/PPARα-SREBPs pathway
por: He, Jinbiao, et al.
Publicado: (2022)

Obeticholic acid treatment ameliorates the cardiac dysfunction in NASH mice
por: Liu, Szu-Yu, et al.
Publicado: (2022)

Naturally Occurring TPE-CA Maintains Gut Microbiota and Bile Acids Homeostasis via FXR Signaling Modulation of the Liver–Gut Axis
por: Liu, Linlin, et al.
Publicado: (2020)

Corrigendum: Effects of Poria cocos extract on metabolic dysfunction-associated fatty liver disease via the FXR/PPARα-SREBPs pathway
por: He, Jinbiao, et al.
Publicado: (2023)

Effects of Intestinal FXR-Related Molecules on Intestinal Mucosal Barriers in Biliary Tract Obstruction
por: Yan, Meng, et al.
Publicado: (2022)

Akkermansia muciniphila and Bifidobacterium bifidum Prevent NAFLD by Regulating FXR Expression and Gut Microbiota
por: Nian, Fulin, et al.
Publicado: (2023)

Prediction of VEGF-C as a Key Target of Pure Total Flavonoids From Citrus Against NAFLD in Mice via Network Pharmacology
por: Hong, Wei, et al.
Publicado: (2019)

Assessing the Selectivity of FXR, LXRs, CAR, and RORγ Pharmaceutical Ligands With Reporter Cell Lines
por: Toporova, Lucia, et al.
Publicado: (2020)

Diammonium Glycyrrhizinate Ameliorates Obesity Through Modulation of Gut Microbiota-Conjugated BAs-FXR Signaling
por: Li, Yun, et al.
Publicado: (2021)

NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment
por: Xia, Ming-Feng, et al.
Publicado: (2019)

Obeticholic acid for primary biliary cholangitis
Publicado: (2020)

Obeticholic Acid for Primary Biliary Cholangitis
por: Floreani, Annarosa, et al.
Publicado: (2022)

Hepatic Clstn3 Ameliorates Lipid Metabolism Disorders in High Fat Diet-Induced NAFLD through Activation of FXR
por: Guo, Jingyi, et al.
Publicado: (2023)

Berberine Alleviates Non-alcoholic Steatohepatitis Through Modulating Gut Microbiota Mediated Intestinal FXR Activation
por: Shu, Xiangbing, et al.
Publicado: (2021)

Polygoni Multiflori Radix interferes with bile acid metabolism homeostasis by inhibiting Fxr transcription, leading to cholestasis
por: Dai, Yihang, et al.
Publicado: (2023)

Allium victorialis L. Extracts Promote Activity of FXR to Ameliorate Alcoholic Liver Disease: Targeting Liver Lipid Deposition and Inflammation
por: Cui, Zhen-Yu, et al.
Publicado: (2021)

Licraside as novel potent FXR agonist for relieving cholestasis: structure-based drug discovery and biological evaluation studies
por: Xi, Lili, et al.
Publicado: (2023)

(E)-7-Ethylidene-lithocholic Acid (7-ELCA) Is a Potent Dual Farnesoid X Receptor (FXR) Antagonist and GPBAR1 Agonist Inhibiting FXR-Induced Gene Expression in Hepatocytes and Stimulating Glucagon-like Peptide-1 Secretion From Enteroendocrine Cells
por: Stefela, Alzbeta, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e23tqkcp08uit38lmb2jjf1at5